Inhibition of Epithelial TNF-α Receptors by Purified Fruit Bromelain Ameliorates Intestinal Inflammation and Barrier Dysfunction in Colitis

Zijuan Zhou1†, Liang Wang1†, Panpan Feng1†, Lianhong Yin2, Chen Wang3, Shengxu Zhi3, Jianyi Dong1, Jingyu Wang1, Yuan Lin2, Dapeng Chen1*, Yongjian Xiong4,5* and Jinyong Peng2*

1Laboratory Animal Center, Dalian Medical University, Dalian, China, 2College of pharmacy, Dalian Medical University, Dalian, China, 3Dalian Medical University, Dalian, China, 4Central Laboratory, the First Affiliated Hospital, Dalian Medical University, Dalian, China, 5College of Integrative Medicine, Dalian Medical University, Dalian, China

Activation of the TNF-α receptor (TNFR) leads to an inflammatory response, and anti-TNF therapy has been administered to reduce inflammation symptoms and heal mucosal ulcers in inflammatory bowel disease (IBD). Bromelain, a complex natural mixture of proteolytic enzymes, has been shown to exert anti-inflammatory effects. This study aimed to investigate the effect of purified fruit bromelain (PFB)-induced inhibition of epithelial TNF in a rat colitis model. Colitis was established by intracolonic administration of 2, 4, 6-trinitrobenzene sulfonic acid. Expression of TNFR1 and TNFR2 was measured by quantitative RT-PCR and western blotting. The effect of PFB on colitis was evaluated by examining the inflammatory response and intestinal epithelial barrier function. Our results showed that both TNFR1 and TNFR2 expression were significantly increased in a colitis model, and the increase was significantly reversed by PFB. Colitis symptoms, including infiltration of inflammatory cells, cytokine profiles, epithelial cell apoptosis, and epithelial tight junction barrier dysfunction were significantly ameliorated by PFB. Compared with fruit bromelain and stem bromelain complex, the inhibition of TNFR2 induced by PFB was stronger than that exhibited on TNFR1. These results indicate that PFB showed a stronger selective inhibitory effect on TNFR2 than TNFR1. In other words, purification of fruit bromelain increases its selectivity on TNFR2 inhibition. High expression of epithelial TNFRs in colitis was significantly counteracted by PFB. Compared with fruit bromelain and stem bromelain complex, the inhibition of TNFR2 induced by PFB was stronger than that exhibited on TNFR1. These results indicate that PFB showed a stronger selective inhibitory effect on TNFR2 than TNFR1. In other words, purification of fruit bromelain increases its selectivity on TNFR2 inhibition. High expression of epithelial TNFRs in colitis was significantly counteracted by PFB, and PFB-induced TNFR inhibition ameliorated colitis symptoms. These results supply novel insights into potential IBD treatment by PFB.

Keywords: bromelain, purification, inflammation, cytokines, myosin light chain kinase, TNF-α receptor, inflammatory bowel disease, tight junction

INTRODUCTION

Inflammatory bowel diseases (IBDs) are a group of recurrent inflammatory conditions of the colon and small intestine mainly of ulcerative colitis and Crohn’s disease (1). IBDs are important diseases of the gastrointestinal tract and they are associated with costly treatments and a high degree of patient impairment. However, the pathogenesis of colitis remains poorly understood.
Tumor necrosis factor-alpha (TNF-α) is a potent pro-inflammatory cytokine and increased TNF-α production is found in serum, stools, and bowel mucosa in both IBD patients and IBD models (2). Anti-TNF therapy has been confirmed to alleviate symptoms, heal mucosal ulcers, spare corticosteroid treatment, and decrease hospitalization costs. TNF-α leads to the activation of nuclear factor kappa B (NF-κB), which can transmute into the nucleus, and it binds to DNA response elements in gene promoter regions to control transcription of genes, such as inducible NO synthase (iNOS), cyclo-oxygenase-2 (COX2), and myosin light chain kinase (MLCK) (3, 4). Both iNOS and COX2 are pro-inflammatory mediators which play crucial roles in inflammatory responses (3). The expression and activity of MLCK is increased in human IBD and associated with histological evidence of disease activity (5). MLCK-induced phosphorylation of perijunctional actomyosin mediates tight junction loss, which triggers the initiation and development of IBD (6). TNF-α exerts its biological function by binding to two kinds of TNF-α receptors (TNFRs), including TNFR1 and TNFR2. Epithelial TNFR1 and TNFR2 are relatively under-examined, but they have been implicated in epithelial apoptosis, proliferation, migration, and tight junction regulation (7–9).

In general, bromelain is a complex natural mixture of proteolytic enzymes which is derived from pineapple plants (10). Bromelain, a phytotherapeutic drug with the characteristics of efficacy, safety, and lack of undesired side effects after oral administration, has been well accepted in patients (11). Bromelain exerts multiple pharmacological effects, such as preventing edema formation and reducing existing edema, promoting the absorption of antibiotic drugs, affecting blood coagulation and fibrinolysis, as well as anticancer and anti-inflammatory effects (12–14). Oral administration of bromelain relieved IBD symptoms (11, 15, 16); however, the effect of bromelain on intestinal inflammation induced by chemical damage and its underlying mechanisms are still not fully understood.

The present study aimed to examine the effects of purified fruit bromelain (PFB) on TNFRs in a rat colitis model and to determine the role of TNFRs in bromelain-induced alleviation of colitis. The bromelain used in this study is PFB (EC 3.4.22.33, 17 kDa) (17). A rat colitis model was established by intracolonic administration of 2,4,6-trinitrobenzene sulfonic acid (TNBS), which is a classic model for studying IBD (18). The effects of PFB on colitis were also evaluated in vitro using the rat intestinal epithelial cell line IEC-6 and human colon epithelial cell line, Caco-2.

**MATERIALS AND METHODS**

**Animals**

Fifty-four Sprague-Dawley male rats (5–7 weeks old, weighing between 200 and 220 g) were purchased from the experimental animal center at Dalian Medical University [Certificate of Conformity: No. SYXX (Liao) 2013-0006]. The experimental protocol was approved by the Animal Care and Ethics Committee of Dalian Medical University on June 8, 2012. The animal protocol was designed to reduce pain and discomfort in the animals.

The rats were acclimated to laboratory conditions (23°C, 12/12 h light/dark, 50% humidity, ad libitum access to food and water) for 2 weeks prior to the experiments. Rats were housed one per cage and were deprived of food for 12 h before the experiments. All rats were euthanized by barbiturate overdose (intravenous injection, 150 mg/kg pentobarbital sodium) for intestinal tissue collection.

**Reagents**

PFB (EC 3.4.22.33) was purified by us from crude proteins of pineapple by high-speed counter-current chromatography (17). Briefly, Matured Pineapple fruits were purchased from a local store (Dalian, China) and authenticated by Dr. Yunpeng Diao (Dalian Medical University, Dalian, China). Pineapple fruit was used to extract the juice, after the juice refined by centrifugation (10,000 × g, 30 min, 4°C), finely powdered ammonium sulfate was added into the juice gradually to obtain 50% saturation with continuous stirring for 1 h. Overnight aging at 4°C, some precipitate was separated out and recovered by centrifugation at 10,000 × g for 30 min at 4°C. Finally, 7.6 g dry protein was obtained, which was used for subsequently isolation. HSCCC coupled with a reverse micelle solvent system was successfully applied to separate fruit bromelain from fruit of pineapple, and the protein content of separated fraction was reached to 99%, the electrophoresis of obtained fraction purity was 100%, and the activity recovery was 95.5%. Stem bromelain complex (E.C. 3.4.22.32) and sulfasalazine (SASP) were purchased from Tianjin Kingyork Group Co. Ltd. (Tianjin, China). Antibodies to TNFR1 (ab90463), TNFR2 (ab109322), NF-κB, p38, JNK, ERK, Akt, Bax (ab21390), and Bcl-2 (ab13977) were purchased from Abcam Ltd. (Hong Kong, China). Chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA), unless otherwise indicated.

**Cell Culture**

Rat intestinal IEC-6 epithelial cells and human Caco-2 cells were obtained from the cell bank of the Shanghai Institute (Shanghai, China). The cells used in this study were evaluated before the experiments, and no significant interspecies variations in TNFR signaling were observed, which may have affected the results. Cells were maintained at 37°C in a 5% CO2 environment. The culture medium consisted of DMEM with 4.5 mg/mL glucose, 50 U/mL penicillin, 50 U/mL streptomycin, 4 mM glutamine, 25 mM HEPES, and 10% fetal bovine serum. Both fetal bovine serum and DMEM were purchased from Invitrogen (Waltham, MA, USA).

**Experimental Design**

Twenty-four of the 54 rats were used to test the toxicity of bromelain in vivo. The rats were divided randomly into four groups (n = 6) including normal control rats, 2.5, 20, and 160 mg/kg PFB-treated groups. The remaining 30 rats were divided randomly into five groups (n = 6). The rats were treated as follows: group I, sham-operated control with intracolonic administration of saline; group II, colitis group; group III, SASP (100 mg/kg body weight, intragastric, dissolved in saline); group III, low-dose PFB (10 mg/kg body weight, intragastric, dissolved in saline); group
IV, high-dose PFB (80 mg/kg body weight, intragastric, dissolved in saline), 1 day after colitis induction. SASP and PFB were administered by gavage once daily for 14 consecutive days. The rat colitis model was induced as described previously (19). Briefly, rats were fasted for 24 h with free access to drinking water. A catheter was inserted through the anus to approximately the level of the splenic flexure (8 cm proximal to the anal verge) under urethane anesthesia. The colon was then infused with 1 mL of TNBS dissolved in ethanol (50% v/v) at a dose of 125 mg/kg. The rats were allowed to eat and drink *ad libitum* from 1 h after the operation. Distal colon samples from full-thickness intestinal walls were harvested for biochemical studies.

### Table 1: Colitis rat morphology and defecation.

| Condition                        | Revival time (h) | Symptoms                                                                 | Symptom duration                                      | Deaths |
|----------------------------------|------------------|--------------------------------------------------------------------------|--------------------------------------------------------|--------|
| Sham                             | 1                | Loose stools and loss of appetite                                         | First 2 days                                           | 0      |
| TNBS-colitis                     | 2                | Loss of appetite, loose stools, stool frequency increased, outflow of red or dark red liquid from the anus, positive fecal occult blood test | Symptoms peaked on day 3 and lasted for about 7 days, fecal blood was visible. Loose stools were still seen at 7 days following colitis induction, but fecal occult blood tests were negative | 2      |
| SASP                             | 2                | Loose stools, increased stool frequency, outflow of red or dark red liquid from the anus, positive fecal occult blood test, and loss of appetite | Symptoms lasted for about 5 days. No fecal blood was visible after 4 days | 2      |
| 10 mg/kg purified fruit bromelain (PFB) | 2                | Loose stools, increased stool frequency, outflow of red or dark red liquid from the anus, positive fecal occult blood test, and loss of appetite | Symptoms lasted for about 3 days. No fecal blood was visible after 3 days | 1      |
| 80 mg/kg PFB                     | 2                | Loose stools, increased stool frequency, outflow of red or dark red liquid from the anus, positive fecal occult blood test, and loss of appetite | Symptoms lasted for about 4 days. No fecal blood was visible after 3 days | 1      |

TNBS, 2,4,6-trinitrobenzene sulfonic acid; SASP, salicylazosulfapyridine.
FIGURE 2 | Purified fruit bromelain (PFB) alleviated colitis symptoms. Colitis symptoms were examined after 14 days of PFB therapy. (A) Hematoxylin and eosin-staining of rat colonic tissue (20x, scale bar is 100 µm). Effects of PFB on (B) body weight, (C) food intake, (D) macroscopically visible damage, and (E) colon weight-to-length ratio in colitis rats. Data in the sham group are set to a relative value of 100% and expressed as the mean ± SD. Other data are the relative values compared with sham: **P < 0.01 compared with sham group (n = 6 rats); ##P < 0.01 compared with TNBS control group (n = 6 rats). SASP, sulfasalazine.

FIGURE 3 | Purified fruit bromelain (PFB) attenuated neutrophil infiltration and cytokine profiles. Effects of PFB on (A) myeloperoxidase (MPO), (B) TNF-α, (C) IL-1β, and (D) IL-8 in rat colon tissue determined by enzyme-linked immunosorbent assay. Data are expressed as the mean ± SD; **P < 0.01 compared with sham group; ##P < 0.01 compared with TNBS control group (n = 6 rats). SASP, sulfasalazine.
Assessment of Inflammation

Animal body weight and total food intake for each group were measured daily. Macroscopic colon damage was scored on a scale of 0–10 (20). Colon preparations were stained with hematoxylin and eosin (HE), and the results were evaluated according to previously defined morphological criteria (21–23). Levels of myeloperoxidase (MPO) and pro-inflammatory cytokines were examined using enzyme-linked immunoabsorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s instructions.

Intestinal Barrier Function Analysis

Intestinal epithelial barrier function was measured in vivo according to a previous study (19). Briefly, rats received gavage administration of 150 µL (80 mg/mL) fluorescein isothiocyanate-4 kDa dextran (FD-4) (Sigma-Aldrich, St. Louis, MO, USA), before which rats were fasted but free to water for 3 h. One and three hours later, serum was harvested and measured using a Synergy HT plate reader (BioTek, Winooski, VT, USA). Intestinal barrier function in vitro was represented by transepithelial electrical resistance (TER) using an epithelial voltohmeter. Caco-2 cells (4 × 10⁴) were seeded in the upper chamber of a transwell filter. A barrier dysfunction cellular model was established in Caco-2 monolayers exposed to lipopolysaccharide (LPS).

Western Blot Analysis

Colon sections were isolated from rats in each group and immediately stored in liquid nitrogen. Total protein was isolated from epithelial layer of the colon section using a Total Protein Extraction Kit (KeyGen Biotech, Nanjing, China). Blots were transferred to nitrocellulose filters and probed with corresponding antibodies at 4°C with gentle shaking overnight. Bands were detected and quantified using a MultiSpectral Imaging system (UVP, Cambridge, UK).

Cell Transfection

IEC-6 cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) with TNFR1/TNFR2-targeted or control small interfering RNA (siRNA) oligos (Dharmacon, Lafayette, CO, USA), according to the manufacturer’s instructions [Takara Biotechnology (Dalian) Co., Ltd.]. The siRNA sequence for TNFR1/TNFR2 was produced by GenePharma, Ltd. (Shanghai, China). The efficiency of gene silencing was confirmed by western blotting.

Statistical Analysis

The animal experiments, in vitro experiments, and data analyses were conducted according to a single-blind study design. Data were compared among three or more groups using a one-way ANOVA, and between two groups using Student’s t-tests. Data were expressed as the mean ± SD. Data were normally distributed and each group showed similar variances. Further evaluations were carried out using Kruskal–Wallis rank sum tests. All experiments were repeated at least six times and a P value < 0.05 was considered statistically significant.

RESULTS

Dose/Concentration Selection and Toxicity of PFB in Normal Cells and Rats

The cytotoxicity of PFB in cell lines was examined in vitro to determine the effective concentration with no toxicity for subsequent experiments. Exposure to 2.5–160 µg/mL PFB for 36 h had no significant effect on the viability of IEC-6 (Figure 1A). Intragastric administration of PFB (2.5–160 mg/kg) for seven consecutive days had no significant effect on cytokine profiles [TNF-α, interleukin (IL)-1β, and IL-8] (Figures 1B–D) in colon tissue. Furthermore, intragastric administration of PFB had no significant effect on the expression of mRNA and protein of TNFRs (Figures 1E,F). Based on these preliminary experiments and preliminary results reported by other researchers (15, 24), we used <80 mg/kg PFB for in vivo and <80 µg/mL PFB for in vitro experiments in this study.

![Figure 4](image-url)

**FIGURE 4** Purified fruit bromelain (PFB) reversed the increased intestinal permeability. After 14 days of PFB therapy, the intestinal permeability in each group was examined through testing serum recovery of FD-4 in vivo (A) and transepithelial electrical resistance (TER) in Caco-2 cells (B) (n = 6). Cells were incubated with 100 ng/mL lipopolysaccharide (LPS) for 24 h in the presence or absence of PFB. Data in the sham group or normal control (NC) cell group are set to a relative value of 100% and expressed as the mean ± SD. Other data are the relative values compared with sham or NC: *P < 0.01 compared with sham or NC group; **P < 0.01 compared with TNBS control or LPS control group.
Colitis Rat Morphology and Defecation

Colitis symptoms for rats in TNBS group (TNBS-colitis) are shown in Table 1. Rats in the TNBS-colitis group regained consciousness about 2 h after anesthesia. Symptoms included loose stools, increased stool frequency, outflow of red or dark red liquid from the anus, positive fecal occult blood test, and loss of appetite. On day 3, these symptoms peaked and lasted for about 7 days. Seven days following colitis induction, loose stools were still seen in the TNBS-colitis group. Deaths were recorded throughout the experiment, as outlined in Table 1. New rats were added to maintain six rats per group.

PFB Ameliorated Colitis Symptoms

Successful establishment of colitis was confirmed with biochemical and macroscopic analysis. TNBS challenge provoked apparent colonic mucosal injuries, including serious hyperemia, edema, and ulcers, some of which were covered with necrosis on the surface of colonic mucosa. HE-staining revealed remarkable inflammatory cell infiltration even in muscle layers, irregular arrangement of glands, crypt abscesses, and thickened submucosal edema (Figure 2A). In the colitis group, rats had significantly lower body weight (Figure 2B) and lower food intake (Figure 2C) compared with the sham group, as well as more visible macroscopic damage (Figure 2D) and a higher colon weight-to-length ratio (Figure 2E). Colitis rats also had higher MPO activity (indicating neutrophil infiltration into the damaged tissue), higher pro-inflammatory cytokine levels, including TNF-α, IL-1β, and IL-8. PFB (10 and 80 mg/kg) and SASP reversed the pathological changes in the colitis model after 7 and 14 days of drug treatment, suggesting that PFB significantly ameliorated the colitis symptoms (Figures 2 and 3).

PFB Increases Intestinal Permeability

In vivo, intestinal barrier dysfunction leads to increase in serum recovery of FD-4. In single layer of Caco-2 cells, LPS leads to intestinal barrier dysfunction and significant TER reduction. In this study, the serum recovery of FD-4 was significantly increased in the colitis control group compared with the sham group. Gavage administration of PFB significantly reduced the serum recovery of FD-4. In in vitro studies, LPS induced decrease of TER, which was also significantly reversed by PFB (Figure 4). These results suggest that intestinal epithelial barrier dysfunction is recovered by PFB treatment.

**FIGURE 5** | Potential mechanisms underlying purified fruit bromelain (PFB) induced therapeutic effects on colitis. Colonic segments were isolated after 14 days of PFB treatment. Quantitative real-time PCR analysis of TNF-α receptor (TNFR) mRNA (A); Western blotting analysis of TNFR protein (B–D), inflammation marker NF-κB (E,F), tight junction barrier related protein myosin light chain kinase (MLCK) (F,G) and (B,G), apoptosis-related proteins Bax (B,H) and Bcl-2 (B,I). Data are expressed as the mean ± SD. Values in the sham group are set to 100% and other values are given relative to those in the sham group: **P < 0.01 compared with sham group; *P < 0.05 and **P < 0.01 compared with TNBS control group (n = 6 rats).
Potential Mechanisms Underlying PFB-Induced Therapeutic Effects on Colitis

In the TNBS group, expression levels of TNFR1, TNFR2, and NF-κB were significantly increased compared with the sham group, and all of these changes were reversed by treatment with PFB (Figure 5). The apoptosis-related protein Bax was significantly increased and Bcl-2 was significantly decreased in colitis rats, and these changes were also reversed by PFB. The epithelial tight junction dysfunction-related protein MLCK was significantly increased and the tight junction protein occludin was significantly decreased, and these changes were also reversed by PFB treatment. However, the increased expression level of TNFR mRNA was not significantly affected by PFB.

To confirm the role of PFB-induced TNFR inhibition in the treatment of colitis, we examined this effect in IEC-6 cells with or without siRNA targeting TNFR2. In normal cells, LPS induced significant increases in NF-κB and MLCK, which reflects the induction of inflammation and epithelial barrier dysfunction. These increases were significantly inhibited by both 10 and 80 mg/kg PFB (Figure 6). The PFB-induced inhibition of NF-κB and MLCK could be significantly abrogated by inhibition of TNFR2 by RNA interference (Figure 6). Moreover, the PFB-induced inhibition of NF-κB but not MLCK could be abrogated by inhibition of TNFR1 by RNA interference (Figure 7), suggesting that PFB alleviated inflammation and epithelial barrier dysfunction in a TNFR2-dependent manner. The results above suggest that TNFR-regulated inflammation, epithelial apoptosis, and tight junction barrier dysfunction in colitis may be blocked by PFB, which in turn may inhibit the release of cytokines, as well as decrease epithelial permeability.

Comparative Study of PFB with PFB Complex

The bromelain used in this study is PFB, but commercial bromelain is a complex natural mixture of proteolytic enzymes derived from pineapple stems (10). The effect of PFB, fruit bromelain complex, and commercial stem bromelain complex on the expression of TNFR1 and TNFR2 in IEC-6 cells stimulated by LPS was studied. Compared with fruit bromelain and stem bromelain complexes, the inhibition of TNFR2 induced by PFB was stronger than the inhibition of TNFR1. These results indicate that PFB showed a stronger selective inhibitory effect on TNFR2 than TNFR1 (Figure 8).

DISCUSSION

In this study, the expression level of TNFRs including TNFR1 and TNFR2 were significantly increased in a rat colitis model, and PFB-induced reduction of TNFR1 and TNFR2 ameliorated colitis symptoms. Accompanied with an increased expression of

FIGURE 6 | Downregulation of TNFR2 in purified fruit bromelain (PFB)-induced inhibition of inflammation and epithelial barrier dysfunction. Effects of PFB on expression of TNFR2, NF-κB and MLCK in the presence of siRNA targeting TNFR2. (A) Representative Western blotting image for effects of PFB on expression of TNFR2, NF-κB and MLCK; statistical analysis of PFB on the expression of TNFR2 (B), NF-κB (C), and MLCK (D). Representative Western blotting image for effects of PFB on NF-κB and MLCK. Data are expressed as the mean ± SD. Values are given relative to normal control (NC) in si-control (100%) and other values are given relative to the NC group: **P < 0.01 compared with NC; ***P < 0.01 compared with corresponding LPS control.
TNFR, visible macroscopic damage, mucosal inflammation, and tight junction barrier dysfunction in the colitis model were also significantly increased. PFB reversed the pathological changes in the colitis model.

Gavage administration of PFB significantly decreased colitis symptoms which were indicated by HE-staining, macroscopic damage scores, inflammatory response, as well as recovery of intestinal barrier function. In this study, the epithelial TNFR1 and TNFR2 were mainly studied in a colitis model. Both expression changes of TNFR1 and TNFR2 are involved in the inflammatory response in IBD; however, TNFR2 but not TNFR1 is involved in regulation of tight junction barrier function (25). TNFR1 is involved in the activation of apoptosis through several signaling pathways including MAP kinases and NF-κB activation. The activation of apoptosis process is not regulated by TNFR2 (7). Taken together, TNFR1 and TNFR2 may play distinct roles in IBD, which is also confirmed by our study. Although TNFR1 and TNFR2 play distinct roles in IBD, PFB induced reduction of both TNFR1 and TNFR2 resulting in alleviation of colitis. However, further studies are needed to distinguish the exact role of TNFR1 and TNFR2 in IBD.

Intestinal epithelial barrier dysfunction leads to increased intestinal permeability and finally aggravates colitis (26). High expression level of MLCK, induced by TNFR2 activation, plays an important role in the increase of intestinal permeability (27, 28). In this study, the intestinal barrier dysfunction was significantly alleviated by PFB. TNFR2 expression was significantly reduced by PFB, leading to the reduction of MLCK expression. In the SASP-treated group, the high epithelial permeability was not significantly affected by SASP for 14 days after colitis induction.

Bromelain is one kind of protease whose role is thought to involve degradative action of targets at cell surfaces (29). In this study, increased expression of TNFRs in a colitis model was significantly reversed by PFB treatment. The anti-inflammatory effect of bromelain appears to be related to protease activity. However, other effects such as inhibition of cell growth and metastasis are associated with other nonproteolytic components contained in bromelain (24).

Consideration of two aspects of selectivity helps to clarify the therapeutic effect of PFB in colitis. First is the selective inhibition by PFB of TNFRs and other cell membrane receptors which is related to IBD development, such as toll-like receptors; the other is selective inhibition of the different TNFR isoforms, such as TNFR1 and TNFR2. The selective inhibition of TNFR1 and TNFR2 by PFB was compared with commercial bromelain, which is a mixture of cysteine proteases obtained from both pineapple stems and fruits. Results suggested a stronger selective inhibition of TNFR2 than TNFR1, which confirmed the protective effects of PFB on intestinal barrier function. Thus, the determination of the proteolytic activity alone may not be sufficient to completely characterize the pharmacological properties of bromelain. Results also showed PFB in low concentration indicate a stronger inhibition of TNFR1 expression than TNFR2. We speculated that PFB has a stronger drug potency of inhibition on TNFR1 than TNFR2 in low concentration. Another explanation for this is might be due to the presence of trace level of other proteolytic enzyme; however, it needs further study to examine what kinds of proteolytic enzyme has been involved.

In general, the bioactive constituents of natural sources are more promising candidates for new drug discoveries than specific agonists (30, 31). Purified bromelain is easily obtainable from natural sources because our previous study showed that the content of purified bromelain in pine apple fruit is about 0.15% (g/g). These data showed that purified bromelain is easily obtainable from natural sources and pineapple fruit maybe beneficial for the treatment and prevention of intestinal inflammation. However, the factors including drug stability and controllability in pineapple stem and fruit are not involved. The present study was a preliminary study, with some experimental limitations. The potential toxicological effects of higher concentrations of PFB need to be determined in future studies. The results of the present study provide some novel
insights into the mechanisms and potential therapeutic use of the natural product PFB in IBD.

ETHICS STATEMENT

Fifty-four Sprague-Dawley male rats (5–7 weeks old, weighing 200–220 g) were bought from the experimental animal center, Dalian Medical University [Certificate of Conformity: No. SYXK (Liao) 2013-0006]. The experimental protocol was approved by Animal Care and Ethics Committee of Dalian Medical University at June 8, 2012. The animal protocol was designed to reduce pain and discomfort to the animals. The rats were acclimatized to laboratory conditions (23°C, 12/12 h light/dark, 50% humidity, ad libitum access to food and water) for 2 weeks prior to the experiments. Rats were housed one per cage and were deprived of food for 12 h before the experiments. All rats were euthanized by barbiturate overdose (intravenous injection, 150 mg/kg pentobarbital sodium) for intestinal tissue collection.

AUTHOR CONTRIBUTIONS

DC, YX, JP, YL, and JW designed the research; ZZ, LW, PF, LY, CW, SZ, and JD performed the experiments; ZZ, LW, and PF analyzed the data; DC and YX wrote the manuscript. All authors read and approved the final manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (81600440).
References

1. Podoisky DK. Inflammatory bowel disease. N Engl J Med (2002) 347(6):417–29. doi:10.1056/NEJMra020831
2. Billiet T, Ruigear P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-alpha for the treatment of inflammatory bowel disease. Expert Opin Biol Ther (2014) 14(1):75–101. doi:10.1517/14712598.2014.858695
3. Dou W, Zhang J, Sun A, Zhang E, Ding L, Mukherjee S, et al. Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling. Br J Nutr (2013) 110(4):599–608. doi:10.1017/S0007114512005594
4. Jie H, Li JH, Bai G, Shen GS, Jing C, Liu JN, et al. Acanthopanax senticosus polysaccharides-induced intestinal tight junction injury alleviation via inhibition of NF-κB/MLCK pathway in a mouse endotoxemia model. World J Gastroenterol (2017) 23(12):2175–84. doi:10.3748/wjg.v23.i12.2175
5. Blair SA, Kane SV, Clough BT, Turner JR. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest (2006) 86(2):191–201. doi:10.1038/labinvest.3700373
6. Suzuki M, Nagashi T, Yamazaki M, Onizawa M, Watabe T, Sakamaki Y, et al. Myosin light chain kinase expression induced via tumor necrosis factor receptor 2 signaling in the epithelial cell regulates the development of colitis-associated carcinogenesis. PLoS One (2014) 9(2):e88369. doi:10.1371/journal.pone.0088369
7. Chen D, Xiong Y, Lin Y, Tang Z, Wang J, Wang L, et al. Capsaicin alleviates abnormal intestinal motility through regulation of enteric motor neurons and MLCK activity: relevance to intestinal motility disorders. Mol Nutr Food Res (2015) 59(9):1482–90. doi:10.1002/mnr.f.2015005039
8. Corredor J, Yan F, Shen CC, Tong W, John SK, Wilson G, et al. Tumor necrosis factor regulates intestinal epithelial cell migration by receptor-dependent mechanisms. Am J Physiol Cell Physiol (2003) 284(4):C953–61. doi:10.1152/ajpcell.00309.2002
9. Wang F, Schwarz BT, Graham WV, Wang Y, Su L, Clayburgh DR, et al. IFN-γ-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology (2006) 131(4):1153–63. doi:10.1053/j.gastro.2006.08.022
10. Barrett AJ, Woessner JF, Rawlings ND. Handbook of Proteolytic Enzymes. (Vol. 1). Cambridge: Elsevier (2004).
11. Rathnaveenu V, Altheen NB, Soolia K, Kanagesan S, Ramesh R. Potential role of bromelain in clinical and therapeutic applications. Biomed Rep (2016) 5(3):283–8. doi:10.3892/bjr.2016.720
12. Chobotova K, Vemalis AB, Majid FA. Bromelain’s activity and potential as a medicinal plant with intestinal anti-inflammatory activity in TNBS model of intestinal inflammation in rats. J Ethnopharmacol (2014) 151(1):380–5. doi:10.1016/j.jep.2013.10.056
13. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinico-pathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest (1993) 69(2):238–49.
14. Ghia JE, Binnerhassett P, Collins SM. Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression. J Clin Invest (2008) 116(2):2209–18. doi:10.1172/JCI32849
15. Schwæne RC, Marcon R, Meotti FC, Bento AF, Dutra RC, Pizzolattì MG, et al. Oral administration of the flavonoid myricitrin prevents dextran sulfate sodium-induced experimental colitis in mice through modulation of PI3K/Akt signaling pathway. Mol Nutr Food Res (2013) 57(11):1938–49. doi:10.1002/mnr.f.201300134
16. Bhati K, Prasad S, George J, Shukla Y. Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-κappa B against skin tumor-initiation triggering mitochondrial death pathway. Cancer Lett (2009) 282(1):167–76. doi:10.1016/j.clet.2009.03.003
17. Stillie R, Stadnyk AW. Role of TNF receptors, TNFR1 and TNFR2, in dextran sulfate sodium-induced colitis. Inflamm Bowel Dis (2009) 15(10):1515. doi:10.1002/ibd.20951
18. Zhao J, Ng SC, Lei Y, Yi F, Li J, Xu L, et al. First prospective, population-based inflammatory bowel disease incidence study in mainland of China: the emergence of “western” disease. Inflamm Bowel Dis (2013) 19(9):1839–45. doi:10.1097/MIB.0b013e31828a6551
19. Feng Y, Tietelbaum DH. Tumour necrosis factor-α-induced loss of intestinal barrier function requires TNFR1 and TNFR2 signalling in a mouse model of total parental nutrition. J Physiol (2013) 591(15):3709–23. doi:10.1113/ physiol.2013.235318
20. Su L, Nalle SC, Shen L, Turner ES, Singh G, Breskin LA, et al. TNFRI activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology (2013) 145(2):407–15. doi:10.1053/j.gastro.2013.04.011
21. Smyth MJ, O’Connor MD, Trapani JA. Granzymes: a variety of serine protease specificities encoded by genetically distinct subfamilies. J Leukoc Biol (1996) 60(5):555–62.
22. Apprendino G, Minassi A, Tagliatelascafati O. Recreational drug discovery: natural products as lead structures for the synthesis of smart drugs. Nat Prod Rep (2014) 31(7):880–904. doi:10.1039/c3np00010b
23. Kaasip S, Sablani SS. International collaboration in drug discovery and development from natural sources. Pure Appl Chem (2006) 77(11):1923–42.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.